Show your heart a little love this Valentine’s Day.
Take the Listen To Your Heart Challenge!
Everyone who completes the challenge by Heart Valve Disease Awareness Day
(February 22) will be entered to win a $50 Amazon gift card.
Published March 24, 2022
In June 2021, the Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s disease–the first new therapy Alzheimer’s therapy in almost 20 years. But in January 2022, the Centers for Medicare and Medicaid Services (CMS) announced it has no plans to cover the treatment for most seniors. Even worse, CMS’ decision will extend to future FDA approved Alzheimer’s treatments in this class of drugs. So on March 15, 2022, patients and advocates gathered to make sure their voices were heard. This video shares highlights from the rally.
The Accelerate Cures/Treatments for All Dementias (ACT-AD) held a webinar on July 13, 2021 for an in-depth…more.
On December 7, 2020, ACT-AD held a webinar on cutting-edge research on Lewy Body dementia (LBD). The webinar…more.
The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition held an educational webinar on April 18, 2019 on…more.
The Alzheimer’s Disease Policy Task Force is an ad hoc coalition of patient, family caregiver, and professional organizations, working collectively to organize and educate the Alzheimer’s disease community and decisionmakers on the Food & Drug Administration’s (FDA) Accelerated Approval pathway, and the Centers for Medicare & Medicaid Services’ (CMS) coverage determination processes for amyloid-targeted monoclonal antibody therapies for the treatment of Alzheimer’s disease.